Market Overview

POZEN Announces PA32540 Provides Superior Antiplatlet Effects over a Standard of Care Regimen in a Phase 1 Study ("Co-Rx")

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to
transforming medicine that transforms lives, announced the presentation
of Phase 1 data, at the European Society of Cardiologists 2012 Congress,
from a study of PA32540, a novel coordinated-delivery tablet of
enteric-coated (EC) aspirin (325 mg) and immediate-release (IR)
omeprazole (40 mg). The data from the Co-Rx Study (pronounced “Co-Rex”)
suggest that PA32540 given in conjunction with clopidogrel, dosed at
least 10 hours apart, resulted in greater antiplatelet effects than
synchronously administered EC aspirin (81 mg), clopidogrel (75 mg), and
EC omeprazole (46.5% versus 39.9%, respectively, at day 7: 95%
confidence interval of the difference [2.57, 11.91]; p=0.004), in
healthy volunteers. These data were further presented at the European

See full press release

Posted-In: News

 

Related Articles (POZN)

Around the Web, We're Loving...

Get Benzinga's Newsletters